Korean J Helicobacter Up Gastrointest Res.
2013 Sep;13(3):173-181. 10.7704/kjhugr.2013.13.3.173.
Therapeutic Efficacy of Gliptide (Sulglycotide 200 mg): A Double Blinded, Randomized, Active Drug Comparative, Multicenter Study
- Affiliations
-
- 1Department of Internal Medicine, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea.
- 2Department of Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, College of Medicine, Seoul, Korea.
- 3Department of Internal Medicine, Guro Hospital, Korea University College of Medicine, Seoul, Korea.
- 4Department of Internal Medicine, Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
- 5Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
- 6Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- 7Department of Internal Medicine, Ulsan University College of Medicine, Asan Medical Center, Seoul, Korea.
- 8Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
- 9Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.
- 10Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea. jjkim@skku.edu
- KMID: 2249483
- DOI: http://doi.org/10.7704/kjhugr.2013.13.3.173
Abstract
- BACKGROUND/AIMS
Sulglycotide is a non-systemic drug, used in the treatment of peptic ulcer and gastritis. The aim of this study was to assess the therapeutic effect and safety of Gliptide (sulglycotide 200 mg) in comparison with Mucosta (rebamipide 100 mg) for treatment of gastritis.
MATERIALS AND METHODS
Two hundred and three symptomatic patients with erosive gastritis at endoscopy were randomized to receive sulglycotide or rebamipide for four weeks. Therapeutic effects of the drugs for gastritis were evaluated by follow up endoscopic scoring systems and clinical symptoms. We also sought possible adverse effects of the two drugs.
RESULTS
Gliptide (sulglycotide) and Mucosta (rebamipide) treatment in symptomatic gastritis resulted in endoscopic improvement rates of gastritis by 52.0%, 60.6% in intention-to-treat (ITT) analysis, 53.4%, 61.1% in per protocol (PP) analysis, which means therapeutic effects was not different between the two groups. The symptom improvement rates in the sulglycotide and rebamipide treated group were 57.3%, 57.5% in ITT analysis, 54.7%, 58.8% in PP analysis, which mean statistically no significant difference between the two groups. Endoscopic findings such as cure rates of erosion, edema, improvement rates of redness, hemorrhage were not significantly different between the two groups. No statistical significant differences were observed for adverse events between the two groups. The results of 95% CIs for the difference in endoscopic improvement rate and symptom improvement rate met the criteria for the non-inferiority of sulglycotide to rebamipide.
CONCLUSIONS
These results demonstrate that Gliptide (sulglycotide) was not inferior to Mucosta (rebamipide) for endoscopic and symptomatic improvements for symptomatic erosive gastritis.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Single Blinded, Randomized, Active Drug Comparative, Multi-center Study to Evaluate the Therapeutic Efficacy of Gliptide(R)Tab (Sulglycotide 200 mg) in Gastritis Patients; Phase IV Study
- Therapeutic Efficacy of Gliptide(R) (Sulglycotide) on Gastritis - A Double Blind, Randomized, Active Drug Comparative, Multi-Center, Phase IV Study
- Efficacy and Safety of Naftopidil in Patients With Neurogenic Lower Urinary Tract Dysfunction: An 8-Week, Active-Controlled, Stratified-Randomized, Double-Blind, Double-Dummy, Parallel Group, Noninferiority, Multicenter Design
- An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies
- Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
